Home LoginSearchHelpPassword Retrieval Contact Us
Get your FREE FTW Catalog today!
START HERE
| How to Use this Website
| About Michael C. Ruppert & FTW
| Why Subscribe?
| The World Since September 11th
| C.I.A. & Drugs
| Politics
| Regional Conflicts
| The Economy
| Pandora's Box
| Hall of Unsung Heroes
| The Forum
| Upcoming Events
| Store Main Page
| New Products
| Package Deals
| Subscribe to FTW
| FTW Back Issues
| Videos & DVDs
| Special Investigations
| Books & Magazines
| Renewals
| Donations
| FTW CATALOG
| Economy Watch
| About Michael C. Ruppert
| Recommended Reading
| Links
| Whistle Blowers
| Copyright Policy
| Terms & Conditions
| Privacy Policy
| Site Map
FTW P.O. Box 6061-350 Sherman Oaks, CA 91413 Phone: (818) 788-8791 E-mail: service@copvcia.com
1998 - 2003© Copyright From The Wilderness Publications
International Resistance to Mass Smallpox Vaccinations Turning Up by Michael C. Ruppert [© Copyright, 2003, From The Wilderness Publications, www.fromthewilderness.com. All rights reserved. May be copied, distributed or posted on the Internet for non-profit purposes only.] (revised Jan 7, 2002 – 0030 hrs) Jan. 7, 2003, 16:00 PST (FTW) -- With mounting evidence of the dangers inherent in mass smallpox vaccinations and widespread skepticism about the efficacy and need for such measures, a clear pattern is emerging that perhaps the U.S. government and its allies -- particularly Israel -- are not going to have an easy sell with these programs. The Washington Post reported on Dec. 18 that two "prominent teaching hospitals" are refusing to vaccinate their employees against smallpox, even though their staffs would be among the first responders in the event of a biological attack. Officials at Grady Memorial Hospital in Atlanta and at the Virginia Commonwealth University in Richmond cited the risk of dangerous side effects and possible inadvertent contamination of patients by vaccinated workers as grounds for their refusals. In Israel, as reported by Ha'aretz on Dec. 30, "Nearly half of the Meuhedet HMO's staff [in Tel Aviv] have refused to take the smallpox vaccine being offered by the government." The refusals are widespread throughout the Israeli health care system and have also included some members of Israel's security forces and rescue squads. These refusals are as much a PR blow to the Bush Administration and the Israeli government as anything else. And they indicate that significant portions of the global population have serious doubts about deeper agendas that possibly lie beneath government warnings about bioterror attacks. Earlier this year President Bush signed a bioterrorism response bill providing huge windfall profits for pharmaceutical companies. Bush followed that by issuing orders through the Justice Department asking a court in a civil case to seal records that have linked mandatory childhood vaccinations as a possible cause of autism. The recently passed Homeland Security bill also provides immunity for vaccine makers in the event that recipients of vaccines become ill or die after being vaccinated. Under current Food and Drug Administration regulations, smallpox vaccines do not have to be certified for efficacy prior to being introduced into the general population. A complex pattern of state and federal legislation is, however, rapidly falling into place, which would allow the government to make refusing a vaccination a crime, punishable by incarceration, and which would also permit forced vaccinations in declared health emergencies. [The Following Story was Posted Today on CNN – It's All About How The Money Works] ---------- Vaccine market set for growth Merrill Lynch sees $10B in global revenue from vaccines in '06 vs. $5.4B in '01; Flu drugs to lead. January 7, 2003: 6:39 AM EST LONDON (Reuters) - Sales of vaccines, once considered a commodity market, are booming with global revenues set to reach nearly $10 billion in 2006 from $5.4 billion in 2001, according to research published Tuesday. Analysts at Merrill Lynch said the fastest growing section of the market would be for flu vaccines, sales of which are expected to more than double to $2 billion in the next five years. Much of the flu vaccine market's 16 percent compound five-year growth will be driven by the entry of MedImmune Inc. (MEDI: Research, Estimates)'s premium priced nasal spray FluMist, which will be co-marketed by Wyeth (WYE: Research, Estimates). The launch of FluMist later this year, coupled with increasing demand for pediatric vaccines, could see the overall market leap by 20 percent in 2003 alone. Growth is then expected to moderate to an annual 10 percent from 2004 to 2006. Merrill's projection of 13 percent compound five-year sales growth for the total vaccine market compares with global drug sales growth of just eight percent in the year to October, 2002, according to healthcare information firm IMS Health. The infant sector currently makes up the largest section of the vaccine market, with 2001 sales of $2.5 billion, but adult demand is growing as governments actively promote flu shots for the elderly and more vaccines are used by tourists. At the same time, the threat of bioterrorism after the Sept. 11 attacks on the United States has spawned a new business in supplying vaccines against smallpox following fears the deadly virus might be used as a weapon. The global vaccines market is currently dominated by four large pharmaceutical companies -- Aventis SA (AVE: Research, Estimates), GlaxoSmithKline Plc (GSK: Research, Estimates)., Wyeth and Merck & Co. Inc (MRK: Research, Estimates). -- which together account for almost 85 percent of sales. But a number of smaller companies are also carving out a niche, including Britain's PowderJect Pharmaceuticals Plc. and Acambis Plc (ACAM: Research, Estimates)., Switzerland's Berna Biotech and Chiron Corp (CHIR: Research, Estimates). of the U.S. Merrill said it had initiated coverage of PowderJect with a "buy" recommendation, reflecting its strength in flu and travel vaccines, while Berna Biotech was started as "neutral." Acambis, however, was rated a "sell." The brokerage predicted it would start losing money in 2005, after a period of profitability on the back of U.S. government contracts for smallpox vaccine. -------------------------------------------------------------------------------- Copyright 2003 Reuters. All rights reserved. REPOSTED UNDER FAIR USE COPYRIGHT LAWS Find this article at: http://money.cnn.com/2003/01/07/news/companies/vaccines.reut/index.htm
FROM email: Your name: TO email: |  |
Sign Up Here for FREE Email Alerts! [Subscribe to the From The Wilderness Newsletter] Become a Member Today!